Acrivon Therapeutics (ACRV) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.64, -6.82% vs the prior close of $1.76.
- Volume 261.58K shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ACRV slides 6.8% to $1.64, a 1-month low. Closed at $1.64, -6.82% vs the prior close of $1.76. Day range $1.63–$1.77, opened at $1.75.
ACRV daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ACRV slides 6.8% to $1.64, a 1-month low
- Closed at $1.64, -6.82% vs the prior close of $1.76. Day range $1.63–$1.77, opened at $1.75.
- Volume was 261.58K shares, 0.8x its 50-day average of 327.45K.
- Price is -17.1% vs its 50-day average ($1.98) and -8.4% vs its 200-day average ($1.79).
- 52-week range $1.27–$3.56; today's close sits at 16% of that range, 53.9% below the 52-week high.
Oct 15, 2026 — ACRV rises 2.3% to $1.76
- Closed at $1.76, +2.33% vs the prior close of $1.72. Day range $1.71–$1.80, opened at $1.74.
- Volume was 114.50K shares, 0.3x its 50-day average of 331.54K — lighter than usual.
- Price is -11.0% vs its 50-day average ($1.98) and -1.9% vs its 200-day average ($1.79).
- 52-week range $1.27–$3.56; today's close sits at 21% of that range, 50.6% below the 52-week high.
Oct 14, 2026 — ACRV dips 1.7% to $1.72, 3 down days in a row
- Closed at $1.72, -1.71% vs the prior close of $1.75. Day range $1.70–$1.81, opened at $1.73.
- Volume was 214.60K shares, 0.6x its 50-day average of 330.93K.
- Price is -12.9% vs its 50-day average ($1.98) and -4.3% vs its 200-day average ($1.80).
- 52-week range $1.27–$3.56; today's close sits at 20% of that range, 51.7% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ACRV slides 7.9% to $1.75
- Closed at $1.75, -7.89% vs the prior close of $1.90. Day range $1.74–$1.87, opened at $1.86.
- Volume was 477.20K shares, 1.5x its 50-day average of 326.23K.
- Price is -11.3% vs its 50-day average ($1.97) and -2.8% vs its 200-day average ($1.80).
- 52-week range $1.27–$3.56; today's close sits at 21% of that range, 50.8% below the 52-week high.
Oct 12, 2026 — ACRV dips 0.5% to $1.90
- Closed at $1.90, -0.52% vs the prior close of $1.91. Day range $1.87–$1.93, opened at $1.91.
- Volume was 140.20K shares, 0.4x its 50-day average of 333.55K — lighter than usual.
- Price is -3.5% vs its 50-day average ($1.97) and +5.3% vs its 200-day average ($1.80).
- 52-week range $1.27–$3.56; today's close sits at 28% of that range, 46.6% below the 52-week high.
Oct 9, 2026 — ACRV rises 2.1% to $1.91
- Closed at $1.91, +2.14% vs the prior close of $1.87. Day range $1.86–$1.96, opened at $1.88.
- Volume was 192.00K shares, 0.6x its 50-day average of 337.38K — lighter than usual.
- Price is -2.6% vs its 50-day average ($1.96) and +5.7% vs its 200-day average ($1.81).
- 52-week range $1.27–$3.56; today's close sits at 28% of that range, 46.3% below the 52-week high.
Oct 8, 2026 — ACRV dips 0.5% to $1.87
- Closed at $1.87, -0.53% vs the prior close of $1.88. Day range $1.78–$1.90, opened at $1.89.
- Volume was 419.70K shares, 1.2x its 50-day average of 344.31K.
- Price is -4.2% vs its 50-day average ($1.95) and +3.4% vs its 200-day average ($1.81).
- 52-week range $1.27–$3.56; today's close sits at 26% of that range, 47.5% below the 52-week high.
Oct 7, 2026 — ACRV rises 1.1% to $1.88
- Closed at $1.88, +1.08% vs the prior close of $1.86. Day range $1.82–$1.91, opened at $1.85.
- Volume was 283.50K shares, 0.8x its 50-day average of 343.34K.
- Price is -3.3% vs its 50-day average ($1.94) and +3.9% vs its 200-day average ($1.81).
- 52-week range $1.27–$3.56; today's close sits at 27% of that range, 47.2% below the 52-week high.
Oct 6, 2026 — ACRV slides 6.1% to $1.86, 5 down days in a row
- Closed at $1.86, -6.06% vs the prior close of $1.98. Day range $1.85–$2.07, opened at $2.00.
- Volume was 158.30K shares, 0.5x its 50-day average of 343.17K — lighter than usual.
- Price is -4.0% vs its 50-day average ($1.94) and +2.7% vs its 200-day average ($1.81).
- 52-week range $1.27–$3.56; today's close sits at 26% of that range, 47.8% below the 52-week high.
- That makes 5 straight losses.
Oct 5, 2026 — ACRV dips 0.5% to $1.98, 4 down days in a row
- Closed at $1.98, -0.50% vs the prior close of $1.99. Day range $1.91–$2.04, opened at $1.99.
- Volume was 402.10K shares, 1.2x its 50-day average of 340.28K.
- Price is +2.5% vs its 50-day average ($1.93) and +9.1% vs its 200-day average ($1.81).
- 52-week range $1.27–$3.56; today's close sits at 31% of that range, 44.4% below the 52-week high.
- That makes 4 straight losses.
Oct 2, 2026 — ACRV dips 1.0% to $1.99, 3 down days in a row
- Closed at $1.99, -1.00% vs the prior close of $2.01. Day range $1.99–$2.06, opened at $2.05.
- Volume was 205.10K shares, 0.6x its 50-day average of 341.09K.
- Price is +3.4% vs its 50-day average ($1.92) and +9.6% vs its 200-day average ($1.82).
- 52-week range $1.27–$3.56; today's close sits at 31% of that range, 44.1% below the 52-week high.
- That makes 3 straight losses.
ACRV latest news & SEC filings
Every SEC filing by or about ACRV in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Miller Mary sold 294 shares at $1.99 (≈$585) on Oct 5, 2026; now holds 81,715
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 27, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Blume-Jensen Peter sold 14,036 shares at $2.21 (≈$31.02K) on Aug 25, 2026
- Blume-Jensen Peter sold 14,036 shares at $2.21 (≈$31.02K) on Aug 25, 2026
- Masson Kristina sold 14,036 shares at $2.21 (≈$31.02K) on Aug 25, 2026
- Masson Kristina sold 14,036 shares at $2.21 (≈$31.02K) on Aug 25, 2026
- Blume-Jensen Peter sold 14,036 shares at $2.21 (≈$31.02K) on Aug 25, 2026
- Blume-Jensen Peter sold 14,036 shares at $2.21 (≈$31.02K) on Aug 25, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 25, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Peterson Katharine sold 101 shares at $2.01 (≈$203) on Aug 18, 2026
- Peterson Katharine sold 101 shares at $2.01 (≈$203) on Aug 18, 2026
- Peterson Katharine sold 101 shares at $2.01 (≈$203) on Aug 18, 2026
- Peterson Katharine sold 101 shares at $2.01 (≈$203) on Aug 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$17.96M (prior year -$21.01M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.43 (prior year -$0.55) (loss narrowed vs Jun 30, 2025)
Things to know before you trade ACRV
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Mar 19, 2026, Jan 8, 2026. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.03% (largest 8.6%). That is a volatile stock.
- Liquidity: about 278.12K shares (≈$456.12K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.64 vs a range of $1.27–$3.56 (16% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Peter Blume-Jensen sold 14,036 shares on Aug 25, 2026.
- Latest filings: 8-K Aug 12, 2026; 10-Q Aug 12, 2026; 8-K Jun 17, 2026.
- Share count: 42.85M shares outstanding (Aug 7, 2026), +36.2% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ACRV market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.75 | 1.77 | 1.63 | 1.64 | 261.58K |
| Oct 15, 2026 | 1.74 | 1.80 | 1.71 | 1.76 | 114.50K |
| Oct 14, 2026 | 1.73 | 1.81 | 1.70 | 1.72 | 214.60K |
| Oct 13, 2026 | 1.86 | 1.87 | 1.74 | 1.75 | 477.20K |
| Oct 12, 2026 | 1.91 | 1.93 | 1.87 | 1.90 | 140.20K |
| Oct 9, 2026 | 1.88 | 1.96 | 1.86 | 1.91 | 192.00K |
| Oct 8, 2026 | 1.89 | 1.90 | 1.78 | 1.87 | 419.70K |
| Oct 7, 2026 | 1.85 | 1.91 | 1.82 | 1.88 | 283.50K |
| Oct 6, 2026 | 2.00 | 2.07 | 1.85 | 1.86 | 158.30K |
| Oct 5, 2026 | 1.99 | 2.04 | 1.91 | 1.98 | 402.10K |
| Oct 2, 2026 | 2.05 | 2.06 | 1.99 | 1.99 | 205.10K |
| Oct 1, 2026 | 2.02 | 2.12 | 2.00 | 2.01 | 316.90K |
| Sep 30, 2026 | 2.09 | 2.16 | 2.04 | 2.05 | 175.10K |
| Sep 29, 2026 | 2.05 | 2.12 | 2.05 | 2.08 | 132.50K |
| Sep 28, 2026 | 2.08 | 2.12 | 2.03 | 2.06 | 231.00K |
| Sep 25, 2026 | 2.12 | 2.13 | 2.07 | 2.10 | 181.90K |
| Sep 24, 2026 | 2.10 | 2.15 | 2.04 | 2.12 | 316.70K |
| Sep 23, 2026 | 2.14 | 2.17 | 2.03 | 2.06 | 433.20K |
| Sep 22, 2026 | 2.04 | 2.24 | 2.01 | 2.15 | 572.50K |
| Sep 21, 2026 | 1.89 | 2.03 | 1.87 | 2.01 | 333.90K |
About Acrivon Therapeutics
Acrivon Therapeutics (ACRV) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WATERTOWN, MA. Fiscal year ends December 31. SEC CIK 1781174.
ACRV board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Charles M Baum | Director | Jun 22, 2026 |
| Peter Blume-Jensen | President and CEO | Aug 27, 2026 |
| Derek Dirocco | Director | Jun 22, 2026 |
| Peter Kolchinsky | Director | Jun 22, 2026 |
| Ivana Magovcevic-Liebisch | Director | Jun 22, 2026 |
| Kristina Masson | EVP - Business Operations | Aug 27, 2026 |
| Santhosh Palani | Director | Jun 22, 2026 |
| Capital Management, L.P. Ra | Director | Jun 22, 2026 |
| Capital Healthcare Fund Lp Ra | Director | Jun 22, 2026 |
| Capital Nexus Fund Ii, L.P. Ra | Director | Jun 22, 2026 |
| Sharon Shacham | Director | Jun 22, 2026 |
| Rajeev M. Shah | Director | Jun 22, 2026 |
| Michael John Tomsicek | Director | Jun 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Peter Blume-Jensen | President and CEO | Aug 27, 2026 |
| Eric Devroe | Chief Operating Officer | Aug 20, 2026 |
| Erick Gamelin | Chief Development Officer | Aug 20, 2026 |
| Michaela Levin | Chief Business Officer | Sep 2, 2026 |
| Adam D. Levy | Chief Financial Officer | Aug 6, 2026 |
| Kristina Masson | EVP - Business Operations | Aug 27, 2026 |
| Mary Miller | Chief Legal Officer | Aug 20, 2026 |
| Mansoor Raza Mirza | Chief Medical Officer | May 20, 2026 |
| Katharine Peterson | Chief Accounting Officer | Aug 20, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 25, 2026 | Peter Blume-Jensen | Sale | 14,036 | $2.21 |
| Aug 25, 2026 | Peter Blume-Jensen | Sale | 14,036 | $2.21 |
| Aug 25, 2026 | Kristina Masson | Sale | 14,036 | $2.21 |
| Aug 25, 2026 | Kristina Masson | Sale | 14,036 | $2.21 |
| Aug 25, 2026 | Peter Blume-Jensen | Sale | 14,036 | $2.21 |
| Aug 25, 2026 | Peter Blume-Jensen | Sale | 14,036 | $2.21 |
| Aug 25, 2026 | Kristina Masson | Sale | 14,036 | $2.21 |
| Aug 25, 2026 | Kristina Masson | Sale | 14,036 | $2.21 |
| Aug 18, 2026 | Eric Devroe | Sale | 604 | $2.01 |
| Aug 18, 2026 | Eric Devroe | Sale | 604 | $2.01 |
| Aug 18, 2026 | Eric Devroe | Sale | 604 | $2.01 |
| Aug 18, 2026 | Eric Devroe | Sale | 604 | $2.01 |
| Aug 18, 2026 | Katharine Peterson | Sale | 101 | $2.01 |
| Aug 18, 2026 | Katharine Peterson | Sale | 101 | $2.01 |
| Aug 18, 2026 | Katharine Peterson | Sale | 101 | $2.01 |
ACRV financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-77.91M | -2.02 | $-63.66M |
| Dec 31, 2024 | — | $-80.56M | -2.38 | $-65.67M |
| Dec 31, 2023 | — | $-60.39M | -2.74 | $-42.64M |
| Dec 31, 2022 | — | $-31.17M | -7.56 | $-30.12M |
| Dec 31, 2021 | — | $-16.24M | -9.32 | $-13.98M |
Latest balance sheet: total assets $99.09M, total liabilities $12.43M, cash $41.42M (as of Jun 30, 2026).
ACRV earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $1.72 |
| May 13, 2026 | 8-K Item 2.02 (results) | $1.92 |
| Mar 19, 2026 | 8-K Item 2.02 (results) | $1.70 |
| Jan 8, 2026 | 8-K Item 2.02 (results) | $1.93 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $2.07 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $1.31 |
| May 14, 2025 | 8-K Item 2.02 (results) | $1.14 |
| Mar 25, 2025 | 8-K Item 2.02 (results) | $5.39 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $7.93 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Apr 24, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ACRV
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.